SCHEMBL24155656

SCHEMBL24155656

c1ccc(Oc2ncc(-c3cccc4nccn34)cn2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 2/20 0.63
ROCK1 Q13464 2/20 0.63
CHEK1 O14757 1/20 0.63
MAP4K4 O95819 1/20 0.63
CSF1R P07333 1/20 0.63
PRKACA P17612 1/20 0.63
KDR P35968 1/20 0.63
MAP2K1 Q02750 1/20 0.63
ACVR1 Q04771 1/20 0.63
MAP4K2 Q12851 1/20 0.63
DYRK1A Q13627 1/20 0.63
AURKB Q96GD4 1/20 0.63
DYRK1B Q9Y463 1/20 0.63
DRD1 P21728 9/20 0.48
FLT1 P17948 1/20 0.47
CDK9 P50750 1/20 0.47
LIMK1 P53667 1/20 0.47
CLK4 Q9HAZ1 1/20 0.47
MEN1 O00255 1/20 0.46
NPC1 O15118 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24155454 0.77 MEN1 (0.43) CDK8ROCK1CHEK1MAP4K4CSF1R
Hydrochloric Acid SCHEMBL21995536 0.76 MEN1 (0.42) CDK8ROCK1CHEK1MAP4K4CSF1R
SCHEMBL24155477 0.74 MEN1 (0.44) CDK8ROCK1CHEK1MAP4K4CSF1R
SCHEMBL22044431 0.72 KDR (0.55) CDK8ROCK1MAP4K4CSF1RPRKACA
SCHEMBL21995639 0.72 MEN1 (0.52) DYRK1AMEN1NPC1GAARAB9A
SCHEMBL24155451 0.72 MEN1 (0.49) KDRMEN1NPC1GAARAB9A
SCHEMBL15698733 0.71 CDK8 (0.66) CDK8ROCK1CHEK1MAP4K4CSF1R
SCHEMBL24155453 0.69 SCN5A (0.50) DYRK1AMEN1NPC1GAARAB9A
SCHEMBL15690966 0.68 CDK8 (0.72) CDK8ROCK1CHEK1MAP4K4CSF1R
SCHEMBL24155635 0.68 MEN1 (0.63) MEN1NPC1GAARAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210403456-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY SLC6A11, SCN1A, SCN1B CDK8 933/4885ROCK1 2090/4885CHEK1 4662/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.